ClinicalTrials.gg
CompletedNCT02966782Updated May 9, 2023

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

A Phase 1 interventional study of venetoclax and azacitidine in Myelodysplastic Syndromes (MDS), sponsored by AbbVie. Completed at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing venetoclax in Myelodysplastic Syndromes — 17 open to participants now, 27 under way, 2 of them phase 3. venetoclax · Myelodysplastic Syndromes.

Enrollment
17th of 40
70 · median 58
Started
2017
with 1 other
Phase 1
11 of 40
4 open now
Registered
5th of 40
by date
Lead sponsor
3 of 40
AbbVie

Among the 40 studies testing venetoclax in Myelodysplastic Syndromes, this one is the 17th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 1, and was the 5th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

17 of the 40 studies testing venetoclax in Myelodysplastic Syndromes are open now, in 6 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing venetoclax in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).

03

Conditions studied

  • Myelodysplastic Syndromes (MDS)

Keywords

  • Relapsed/refractory
  • Venetoclax
  • Azacitidine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have MDS.
  • Subject enrolled in venetoclax monotherapy must have documented failure of prior therapy with a hypomethylating agent (HMA). HMA-failure is defined as:

    1. Relapse after initial complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years, OR
    2. Failure to achieve complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years
  • Subjects must have presence of \< 20% bone marrow blasts per bone marrow /aspirate at screening.
  • Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation ().
  • Subject must have an (ECOG) performance score of ≤2.
  • Subject must have adequate hematologic, renal, and hepatic function.

Exclusion criteria

Exclusion Criteria:

  • Subject has received prior therapy with a BH3 mimetic.
  • Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).
  • Subject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.
  • Subject has received HSCT or solid organ transplantation.
  • Subject has received a within 4 weeks prior to the first dose of study drug.
  • Subject is pregnant or breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Venetoclax monotherapy (Cohort 1)

    Drug: venetoclax

  • Experimental
    Venetoclax + azacitidine (Cohort 2)

    Drug: venetoclax · Drug: azacitidine

  • Experimental
    Safety Expansion (Cohort 3)

    Drug: venetoclax · Drug: azacitidine

Interventions

  • Tablet

    Also known as: ABT-199, GDC-0199

  • Powder for injection, subcutaneously or intravenous

    Also known as: Vidaza

06

What researchers measure

Primary outcomes

  1. AUCt for azacitidine

    Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for azacitidine

    Time frame: Up to 32 days

  2. Clearance (CL) for azacitidine

    Time frame: Up to 32 days

  3. Cmax for azacitidine

    Maximum plasma concentration (Cmax) of azacitidine

    Time frame: Up to 32 days

  4. Tmax for venetoclax

    Time to Cmax (peak time, Tmax) for venetoclax

    Time frame: Up to 32 days

  5. Recommended Phase 2 Dose (RPTD) and dosing schedules of venetoclax as monotherapy and in combination with azacitidine

    Time frame: Measured from Day 1 until day 28 per dose level.

  6. AUC[0 to infinity] for azacitidine

    Area under the plasma concentration-time curve from Time 0 to infinite time.

    Time frame: Up to 32 days

  7. Tmax for azacitidine

    Time to Cmax (peak time, Tmax) for azacitidine

    Time frame: Up to 32 days

  8. AUC [0-24] for venetoclax

    AUC over a 24-hour dose interval (AUC\[0-24\]) for venetoclax

    Time frame: Up to 32 days

  9. AUCt for venetoclax

    Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for venetoclax

    Time frame: Up to 32 days

  10. Cmax of venetoclax

    Maximum plasma concentration (Cmax) of venetoclax

    Time frame: Up to 32 days

  11. Half-life (t[1/2]) for azacitidine

    Terminal elimination half-life (t\[1/2\]) for azacitidine

    Time frame: Up to 32 days

  12. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: Up to Maximum of 24 months

Secondary outcomes

  1. Event-Free Survival (EFS)

    Time frame: Measured from the date of the first dose of study drug to date of earliest disease progression, death, or initiation of new non-protocol-specified anti-MDS therapy without documented progression, and for up to 5 years after the last subject is enrolled.

  2. Overall Survival (OS)

    Time frame: Measured from the date of first dose of study drug to the date of death, and for up to 5 years after the last subject is enrolled.

  3. Rate of Modified Overall Response (mORR)

    Proportion of participants with a mORR using best outcome will be calculated.

    Time frame: Measured from Cycle 1 Day 1 (C1D1) as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  4. Time to next treatment (TTNT)

    Time frame: Measured from first dose of study drug to start of new non-protocol specified MDS therapy, and for up to 5 years after the last subject is enrolled.

  5. Duration of mORR

    Defined as the number of days from the date of first response (CR, mCR or PR) to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier..

    Time frame: Measured from the date of first response (CR, mCR or PR) to the earliest documentation of progressive disease (PD), and for an anticipated maximum duration of 24 months.

  6. Rate of platelet (PLT) transfusion independence

    Proportion of participants who become platelet transfusion-independent

    Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  7. Time to Transformation acute myeloid leukemia (AML)

    Defined as blast count greater than or equal to 20% in either peripheral blood or bone marrow.

    Time frame: Measured from the date of first dose of study drug to the date of documented AML transformation for an anticipated maximum duration of 24 months.

  8. Progression-Free Survival (PFS)

    Time frame: Measured from the date of the first dose of study drug to the date of earliest disease progression or death, and for an anticipated maximum duration of 24 months.

  9. Overall Response Rate (ORR)

    ORR (equals the sum of rates of complete remission \[CR\] + marrow complete remission (mCR) + partial remission \[PR\]) of venetoclax as a single-agent and in combination with azacitidine.

    Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  10. Complete Remission (CR) Rate

    Proportion of subjects who achieved a complete remission.

    Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  11. Rate of red blood cell (RBC) transfusion independence

    Proportion of red blood cell (RBC) transfusion independence.

    Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  12. Duration of Complete Response (CR)

    Duration of CR will be defined as the number of days from the date of first response CR to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.

    Time frame: Measured from date of first response (CR) to the to the earliest documentation of progressive disease or death of any cause, and for an anticipated maximum duration of 24 months.

  13. Rate of Hematologic Improvement (HI)

    Proportion of participants with HI (erythroid/platelet/neutrophil responses)

    Time frame: Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  14. Rate of marrow complete remission (mCR)

    Proportion of participants with marrow complete remission with or without hematological improvement.

    Time frame: Measured from Cycle 1 Day 1 (C1D1) as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  15. Duration of ORR

    Duration of response (ORR) will be defined as the number of days from the date of first response (CR or PR) to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.

    Time frame: Measured from the date of first response (CR or PR) to the earliest documentation of progressive disease or death of any cause, and for an anticipated maximum duration of 24 months.

07

Study locations

23 sites
  • University of Arizona Cancer Center - North Campus /ID# 157503
    Tucson, Arizona 85719-1478, United States
  • University of Colorado Hospital /ID# 155365
    Aurora, Colorado 80045, United States
  • Yale University /ID# 162544
    New Haven, Connecticut 06510, United States
  • Duplicate_University of Chicago /ID# 155364
    Chicago, Illinois 60637, United States
  • Pediatric Endocrine Associates /ID# 171227
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute /ID# 155361
    Boston, Massachusetts 02215, United States
  • University of Massachusetts - Worcester /ID# 155366
    Worcester, Massachusetts 01655, United States
  • Columbia Univ Medical Center /ID# 156388
    New York, New York 10032-3725, United States
  • Oregon Health and Science University /ID# 155360
    Portland, Oregon 97239, United States
  • University of Texas MD Anderson Cancer Center /ID# 155362
    Houston, Texas 77030, United States
  • St George Hospital /ID# 156037
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital /ID# 155952
    Liverpool, New South Wales 2170, Australia
  • St Vincent's Hospital Melbourne /ID# 155950
    Fitzroy Melbourne, Victoria 3065, Australia
  • The Royal Melbourne Hospital /ID# 155949
    Parkville, Victoria 3050, Australia
  • Royal Perth Hospital /ID# 155951
    Perth, Western Australia 6000, Australia
  • Universitatsklinikum Mannheim /ID# 156038
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • Marien Hospital Duesseldorf /ID# 155518
    Duesseldorf, Nordrhein-Westfalen 40479, Germany
  • Universitaetsklinikum Duesseldorf /ID# 154899
    Düsseldorf, Nordrhein-Westfalen 40225, Germany
  • Universitaetsklinikum Koeln /ID# 155519
    Köln, Nordrhein-Westfalen 50937, Germany
  • Universitaetsklinikum Leipzig /ID# 154897
    Leipzig, Sachsen 04103, Germany
  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 154898
    Dresden, 01307, Germany
  • Universitaetsklinikum Halle (Saale) /ID# 158643
    Halle (Saale), 06120, Germany
  • Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 154896
    Munich, 81675, Germany
08

References and documents

Publications

  • Franke GN, Luckemeier P, Platzbecker U. Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse. Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):1-7. doi: 10.1016/j.clml.2020.10.008. Epub 2020 Oct 16. PubMed 33191169 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Apr 2023, 72 months.

Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 72 months is above that.

Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2016
First posted
Nov 17, 2016
StartActual
Mar 7, 2017
Primary completionActual
Apr 5, 2023
CompletionActual
Apr 5, 2023
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02966782
Lead sponsor
AbbVie
Collaborators
Celgene; Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2016
Start date
Mar 7, 2017
Primary completion
Apr 5, 2023
Completion
Apr 5, 2023
Last update
May 9, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Azacitidine

Start the discussion